Clinical Trial Update: A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and preliminary efficacy of C-CAR011 in patients with refractory diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• C-CAR011

Snippet

Sponsor: Shanghai AbelZeta Ltd. | Conditions: Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Status: COMPLETED